Tags

Type your tag names separated by a space and hit enter

Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies.
Allergy 2013; 68(11):1370-6A

Abstract

BACKGROUND

Diets high in n-3 long chain polyunsaturated fatty acids (LCPUFA) may modulate the development of IgE-mediated allergic disease and have been proposed as a possible allergy prevention strategy. The aim of this study was to determine whether n-3 LCPUFA supplementation of pregnant women reduces IgE-mediated allergic disease in their children.

METHODS

Follow-up of children (n = 706) at hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome randomized controlled trial. The intervention group (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n = 338) received matched vegetable oil capsules without n-3 LCPUFA. The diagnosis of allergic disease was made during medical assessments at 1 and 3 years of age.

RESULTS

No differences were seen in the overall percentage of children with IgE-mediated allergic disease in the first 3 years of life between the n-3 LCPUFA and control groups (64/368 (17.3%) vs 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58-1.06; P = 0.11). Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group had eczema with sensitization compared with 19.0% in the control group (adjusted relative risk 0.75; 95% CI 0.53-1.05; P = 0.10).

CONCLUSIONS

Overall, n-3 LCPUFA supplementation during pregnancy did not significantly reduce IgE-associated allergic disease in the first 3 years of life. Further studies should examine whether the nonsignificant reductions in IgE-associated allergies are of clinical and public health significance.

Authors+Show Affiliations

Women's & Children's Health Research Institute, North Adelaide, SA, Australia; School of Paediatrics and Child Health, University of Western Australia, Subiaco, WA, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24111502

Citation

Palmer, D J., et al. "Randomized Controlled Trial of Fish Oil Supplementation in Pregnancy On Childhood Allergies." Allergy, vol. 68, no. 11, 2013, pp. 1370-6.
Palmer DJ, Sullivan T, Gold MS, et al. Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies. Allergy. 2013;68(11):1370-6.
Palmer, D. J., Sullivan, T., Gold, M. S., Prescott, S. L., Heddle, R., Gibson, R. A., & Makrides, M. (2013). Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies. Allergy, 68(11), pp. 1370-6. doi:10.1111/all.12233.
Palmer DJ, et al. Randomized Controlled Trial of Fish Oil Supplementation in Pregnancy On Childhood Allergies. Allergy. 2013;68(11):1370-6. PubMed PMID: 24111502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies. AU - Palmer,D J, AU - Sullivan,T, AU - Gold,M S, AU - Prescott,S L, AU - Heddle,R, AU - Gibson,R A, AU - Makrides,M, Y1 - 2013/09/21/ PY - 2013/07/01/accepted PY - 2013/10/12/entrez PY - 2013/10/12/pubmed PY - 2014/7/11/medline KW - allergy prevention KW - eczema KW - fatty acids KW - pregnancy KW - randomized controlled trial SP - 1370 EP - 6 JF - Allergy JO - Allergy VL - 68 IS - 11 N2 - BACKGROUND: Diets high in n-3 long chain polyunsaturated fatty acids (LCPUFA) may modulate the development of IgE-mediated allergic disease and have been proposed as a possible allergy prevention strategy. The aim of this study was to determine whether n-3 LCPUFA supplementation of pregnant women reduces IgE-mediated allergic disease in their children. METHODS: Follow-up of children (n = 706) at hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome randomized controlled trial. The intervention group (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n = 338) received matched vegetable oil capsules without n-3 LCPUFA. The diagnosis of allergic disease was made during medical assessments at 1 and 3 years of age. RESULTS: No differences were seen in the overall percentage of children with IgE-mediated allergic disease in the first 3 years of life between the n-3 LCPUFA and control groups (64/368 (17.3%) vs 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58-1.06; P = 0.11). Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group had eczema with sensitization compared with 19.0% in the control group (adjusted relative risk 0.75; 95% CI 0.53-1.05; P = 0.10). CONCLUSIONS: Overall, n-3 LCPUFA supplementation during pregnancy did not significantly reduce IgE-associated allergic disease in the first 3 years of life. Further studies should examine whether the nonsignificant reductions in IgE-associated allergies are of clinical and public health significance. SN - 1398-9995 UR - https://www.unboundmedicine.com/medline/citation/24111502/Randomized_controlled_trial_of_fish_oil_supplementation_in_pregnancy_on_childhood_allergies_ L2 - https://doi.org/10.1111/all.12233 DB - PRIME DP - Unbound Medicine ER -